Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L23a pseudogene 45 (RPL23AP45)
- Target
- RPL23AP45
- Molecular classification
- Other (pseudogene; does not code for a functional protein and is not part of canonical target classes such as enzyme, receptor, transporter, etc.)
01
Overview
Ribosomal protein L23a pseudogene 45 (RPL23AP45) is a processed pseudogene of the ribosomal protein L23a gene dispersed within the human genome[1][4]. As a pseudogene, it is a non-coding segment and is not transcribed into a functional protein. The RPL23AP45 gene is cataloged in gene databases, but there is no evidence supporting its role as a protein-coding gene or as a direct therapeutic target. Some ribosomal protein L23a pseudogenes (such as RPL23AP53) have been studied for regulatory functions and associations with cancer phenotypes, but there are currently no published data on RPL23AP45 with regard to molecular function, disease role, or druggability. Conservation of such pseudogenes suggests some may possess regulatory or as-yet-undescribed biological roles, but these are not yet proven for RPL23AP45[4].
- Other names
- RPL23AP45RPL23A_19_648
02
Mechanism of action
None known (pseudogenes are generally not direct drug targets)
03
Biological functions
Other (specifically, as a pseudogene, it is a non-coding RNA that may have regulatory functions, though any molecular function remains unproven)
04
Disease associations
Other (no direct evidence links RPL23AP45 to specific diseases; functions and disease associations of closely related ribosomal protein L23a pseudogenes (such as RPL23AP53) have been described, but not specifically RPL23AP45)
05
Safety considerations
None known (as there is no direct therapeutic targeting)
06
Interacting drugs
None known (no evidence of drugs targeting this pseudogene)
07
Biomarkers
None known for RPL23AP45 (related L23a pseudogenes, like RPL23AP53, have been associated with biomarker potential in cancer, but RPL23AP45 specifically is not reported as a biomarker)
Beyond the preview
Go deeper on Ribosomal protein L23a pseudogene 45 (RPL23AP45).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ribosomal protein L23a pseudogene 45 (RPL23AP45).